Global Proliferative Diabetic Retinopathy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug Class;
Anti-VEGF and Corticosteroids.By Mode of Administration;
Injectables , Oral and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Proliferative Diabetic Retinopathy Market (USD Million), 2021 - 2031
In the year 2024, the Global Proliferative Diabetic Retinopathy Market was valued at USD 9,953.94 million. The size of this market is expected to increase to USD 15,526.13 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.6%.
The global proliferative diabetic retinopathy (PDR) market is witnessing significant growth, fueled by the increasing prevalence of diabetes worldwide and the subsequent rise in diabetic retinopathy cases. Proliferative diabetic retinopathy, a severe complication of diabetes, occurs when abnormal blood vessels grow on the retina, leading to vision impairment and, if left untreated, irreversible blindness. With the escalating diabetes epidemic, particularly in developing countries, the incidence of PDR is expected to rise, driving demand for effective treatment options and driving growth in the global market for PDR therapeutics and devices.
Advancements in medical technology and treatment modalities are playing a pivotal role in shaping the landscape of the proliferative diabetic retinopathy market. Innovations such as anti-vascular endothelial growth factor (anti-VEGF) injections, laser photocoagulation, and vitrectomy surgery have revolutionized the management of PDR, offering improved outcomes and preserving vision in patients with advanced disease. Additionally, the development of novel drug delivery systems and combination therapies holds promise for enhancing treatment efficacy and reducing the burden of frequent injections or surgical interventions for patients with PDR.
However, the proliferative diabetic retinopathy market faces challenges such as limited access to healthcare services, particularly in underserved regions, and the high cost of PDR treatments and devices. Economic factors, including healthcare expenditure and reimbursement policies, also influence market dynamics and patient access to advanced PDR therapies. Despite these challenges, the growing awareness of diabetic retinopathy screening and early intervention, coupled with ongoing research and development efforts aimed at improving treatment outcomes and reducing treatment burden, are expected to drive continued growth in the global proliferative diabetic retinopathy market in the coming years.
Global Proliferative Diabetic Retinopathy Market Recent Developments
- In June 2022, Regeneron Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application (sBLA) for every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR).
- In February 2022, REGENXBIO Inc. announced additional positive interim data from the ongoing Phase II ALTITUDE trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery.
Segment Analysis
This report extensively covers different segments of Global Proliferative Diabetic Retinopathy Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).
The global proliferative diabetic retinopathy (PDR) market has been segmented based on drug class, mode of administration, and geography, reflecting the diverse array of treatment options and therapeutic approaches available to manage this condition. Within the drug class segment, therapies such as anti-vascular endothelial growth factor (anti-VEGF) agents, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly utilized to inhibit abnormal blood vessel growth and reduce inflammation associated with PDR. Each drug class offers unique mechanisms of action and therapeutic benefits, allowing healthcare providers to tailor treatment regimens based on individual patient needs and disease severity.
The mode of administration segment encompasses various routes through which PDR medications can be delivered to patients, including intravitreal injections, oral tablets, and topical formulations. Intravitreal injections, particularly anti-VEGF agents administered directly into the vitreous cavity of the eye, have emerged as a standard of care for PDR due to their targeted delivery and potent therapeutic effects. However, advancements in drug delivery technology have also led to the development of sustained-release implants and drug-eluting devices, offering prolonged drug release and minimizing the need for frequent injections, thereby improving patient compliance and reducing treatment burden.
Geographically, the global PDR market exhibits regional variations in disease prevalence, healthcare infrastructure, and treatment access, influencing market dynamics and growth opportunities. Developed regions such as North America and Europe lead the market in terms of advanced healthcare services, robust research and development activities, and high adoption rates of innovative PDR therapies. In contrast, emerging economies in Asia-Pacific and Latin America are witnessing rapid growth in PDR prevalence, driven by the increasing incidence of diabetes and improving access to healthcare. As a result, these regions present significant opportunities for market expansion and investment in PDR screening, diagnosis, and treatment initiatives to address the growing burden of diabetic retinopathy.
Global Proliferative Diabetic Retinopathy Segment Analysis
In this report, the Global Proliferative Diabetic Retinopathy Market has been segmented by Drug Class, Mode of Administration and Geography.
Global Proliferative Diabetic Retinopathy Market, Segmentation by Drug Class
The Global Proliferative Diabetic Retinopathy Market has been segmented by Drug Class into Anti-VEGF and Corticosteroids.
The global proliferative diabetic retinopathy (PDR) market has been segmented by drug class into two main categories: anti-vascular endothelial growth factor (anti-VEGF) drugs and corticosteroids. Anti-VEGF drugs, such as ranibizumab, aflibercept, and bevacizumab, are the primary treatment option for PDR. These medications work by inhibiting the activity of vascular endothelial growth factor, a protein that stimulates the growth of abnormal blood vessels in the retina. By blocking this pathway, anti-VEGF drugs help reduce retinal neovascularization and prevent vision loss in patients with PDR, making them a cornerstone of PDR therapy.
In addition to anti-VEGF drugs, corticosteroids are also used in the treatment of PDR, particularly in cases where anti-VEGF therapy may be ineffective or contraindicated. Corticosteroids, such as dexamethasone implants and triamcinolone acetonide injections, exert their therapeutic effects by reducing inflammation and suppressing the immune response in the retina. These medications help alleviate macular edema and improve visual acuity in patients with PDR. However, corticosteroids may be associated with side effects such as increased intraocular pressure and cataract formation, necessitating careful patient monitoring and management.
The segmentation of the global PDR market into anti-VEGF drugs and corticosteroids reflects the diversity of treatment options available to healthcare providers and patients. While anti-VEGF drugs remain the first-line therapy for PDR due to their efficacy and safety profile, corticosteroids offer an alternative treatment approach for patients who may not respond adequately to anti-VEGF therapy. As research and development efforts continue to advance, novel drug delivery systems and combination therapies are being explored to further optimize treatment outcomes and address the complex pathophysiology of PDR.
Global Proliferative Diabetic Retinopathy Market, Segmentation by Mode of Administration
The Global Proliferative Diabetic Retinopathy Market has been segmented by Mode of Administration into Injectables , Oral and Others.
The global proliferative diabetic retinopathy (PDR) market has been segmented by mode of administration into injectables, oral medications, and other delivery methods. Injectables, such as anti-vascular endothelial growth factor (anti-VEGF) injections, are among the primary treatment modalities for PDR. These injections work by inhibiting the growth of abnormal blood vessels in the retina, thereby reducing the progression of diabetic retinopathy and preserving vision in affected individuals. The widespread adoption of anti-VEGF injections has significantly contributed to the growth of the PDR market, offering patients an effective and minimally invasive treatment option.
Oral medications represent another important segment of the proliferative diabetic retinopathy market, providing an alternative mode of administration for managing PDR and its complications. While oral medications may not directly target the underlying cause of diabetic retinopathy like injectables do, they can help control systemic factors such as blood sugar levels, blood pressure, and cholesterol, which contribute to the progression of retinopathy. Oral medications such as anti-diabetic drugs, statins, and angiotensin-converting enzyme (ACE) inhibitors play a crucial role in the comprehensive management of diabetes and its ocular complications, offering patients a more convenient and holistic approach to treatment.
Additionally, the segment of "others" encompasses various delivery methods and emerging technologies for administering treatments for proliferative diabetic retinopathy. This may include intraocular implants, sustained-release drug delivery systems, and gene therapies that are currently under development or in clinical trials. These innovative approaches aim to enhance treatment efficacy, reduce treatment burden, and improve patient outcomes in PDR management. As research and development efforts continue to advance, the "others" segment presents significant opportunities for the expansion and diversification of the global proliferative diabetic retinopathy market, offering new avenues for improving the care and prognosis of individuals affected by this sight-threatening condition.
Global Proliferative Diabetic Retinopathy Market, Segmentation by Geography
In this report, the Global Proliferative Diabetic Retinopathy Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Proliferative Diabetic Retinopathy Market Share (%), by Geographical Region, 2024
In terms of geographical distribution, the global proliferative diabetic retinopathy (PDR) market exhibits variations across different regions. North America, particularly the United States, holds a significant share of the market, driven by factors such as high healthcare expenditure, advanced healthcare infrastructure, and a large diabetic population. The region benefits from extensive screening programs and early intervention initiatives, resulting in a relatively high diagnosis rate of diabetic retinopathy and subsequent demand for PDR treatments and devices. Additionally, the presence of key market players and ongoing research and development activities contribute to the dominance of North America in the global PDR market share.
Europe also commands a notable share of the global PDR market, owing to factors such as increasing diabetes prevalence, favorable government initiatives for diabetic retinopathy management, and well-established healthcare systems. Countries like Germany, the United Kingdom, and France are among the leading contributors to the European PDR market share. Moreover, the region witnesses significant investments in healthcare infrastructure and research, driving innovation in PDR treatment modalities and fostering market growth. However, economic disparities and variations in healthcare access across European countries influence the distribution of PDR treatments and devices within the region.
In contrast, the Asia Pacific region presents both challenges and opportunities for the proliferative diabetic retinopathy market. While the region accounts for a considerable portion of the global diabetic population, particularly in countries like China and India, access to healthcare services and diabetic retinopathy screening programs remains limited in many areas. Nonetheless, increasing healthcare awareness, rising disposable incomes, and efforts to improve healthcare infrastructure are expected to drive market growth in the region. Moreover, collaborations between international healthcare organizations and local stakeholders, coupled with advancements in telemedicine and digital health solutions, hold promise for expanding access to PDR treatments and devices in the Asia Pacific region.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Proliferative Diabetic Retinopathy Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Increasing Prevalence of Diabetes
- Advancements in Treatment Modalities
-
Growing Awareness of Diabetic Retinopathy Screening - The global proliferative diabetic retinopathy (PDR) market is experiencing a significant boost from the growing awareness of diabetic retinopathy screening. Diabetic retinopathy, a common complication of diabetes, can lead to vision loss if left untreated. Increased efforts in educating healthcare providers and diabetic patients about the importance of regular eye examinations for early detection and management of diabetic retinopathy are contributing to a rise in screening rates. As a result, more cases of PDR are being diagnosed at earlier stages, enabling prompt intervention and potentially preserving vision in affected individuals.
Advancements in telemedicine and digital health technologies are expanding access to diabetic retinopathy screening, particularly in underserved and remote areas. Teleophthalmology programs allow for the remote evaluation of retinal images captured by non-specialist healthcare providers using portable fundus cameras. This approach facilitates timely detection of diabetic retinopathy and PDR, even in regions with limited access to ophthalmologists or specialized eye care facilities. By leveraging telemedicine, healthcare systems can reach a broader population and improve the uptake of diabetic retinopathy screening, thereby reducing the burden of vision loss due to PDR.
The integration of diabetic retinopathy screening into routine diabetes care protocols presents opportunities for early intervention and improved patient outcomes. Healthcare providers are increasingly incorporating eye examinations as part of comprehensive diabetes management programs, emphasizing the importance of preventive measures to reduce the risk of vision-threatening complications. As awareness of the link between diabetes and retinopathy grows among both patients and healthcare professionals, the global PDR market stands to benefit from increased screening initiatives, ultimately leading to better vision preservation and quality of life for individuals with diabetes.
Restraints:
- Limited Access to Healthcare Services
- High Cost of Treatments and Devices
-
Economic Factors and Reimbursement Policies - Economic factors and reimbursement policies play a significant role in shaping the dynamics of the global proliferative diabetic retinopathy (PDR) market. The high cost of PDR treatments and devices can pose a barrier to access, particularly in regions with limited healthcare resources and lower income levels. Patients may face challenges in affording costly interventions such as anti-vascular endothelial growth factor (anti-VEGF) injections, laser photocoagulation, or vitrectomy surgery, leading to disparities in access to care and potentially compromising treatment outcomes. Moreover, economic downturns or fluctuations in healthcare expenditure can further exacerbate these challenges, impacting patient affordability and healthcare provider reimbursement.
Reimbursement policies also influence market dynamics and patient access to PDR therapies, as they determine the extent to which treatments are covered by healthcare payers and insurance providers. Variations in reimbursement rates and coverage criteria across different regions and healthcare systems can affect the adoption of advanced PDR treatments and devices. In some cases, limited reimbursement for certain procedures or devices may deter healthcare providers from offering them, resulting in disparities in access to innovative therapies for PDR patients. Additionally, the complexity and administrative burden associated with reimbursement processes can create challenges for healthcare providers, potentially affecting their willingness to adopt new treatments or invest in advanced technologies for PDR management.
Despite these challenges, there are opportunities to address economic factors and reimbursement policies to improve patient access to PDR treatments and devices. Advocacy efforts aimed at raising awareness of the economic burden of untreated diabetic retinopathy and the cost-effectiveness of preventive interventions could help mobilize support for increased healthcare funding and improved reimbursement policies. Moreover, collaborations between healthcare stakeholders, including policymakers, healthcare providers, and industry partners, may facilitate the development of innovative financing models and value-based reimbursement approaches that incentivize the adoption of effective PDR treatments while ensuring equitable access for all patients, regardless of socioeconomic status or geographical location.
Opportunities:
- Development of Novel Drug Delivery Systems
- Expansion of Screening Programs
-
Ongoing Research and Development Efforts - Ongoing research and development efforts are crucial in driving innovation and advancement in the global proliferative diabetic retinopathy (PDR) market. Researchers and pharmaceutical companies are continuously exploring new treatment modalities and therapeutic approaches aimed at improving outcomes for patients with PDR. One area of focus is the development of novel drug delivery systems that offer sustained release of therapeutic agents, reducing the need for frequent injections and improving patient compliance. Additionally, researchers are investigating the potential of combination therapies, including the use of anti-vascular endothelial growth factor (anti-VEGF) agents with other drugs or modalities, to enhance treatment efficacy and address the complex pathophysiology of PDR.
Ongoing research efforts are directed towards understanding the underlying mechanisms of diabetic retinopathy and identifying novel therapeutic targets. By elucidating the molecular pathways involved in the development and progression of PDR, researchers aim to develop more targeted and personalized treatment approaches. This includes exploring the role of inflammation, oxidative stress, and angiogenesis in diabetic retinopathy pathogenesis, as well as investigating the potential of gene therapy and regenerative medicine techniques in promoting retinal repair and regeneration in patients with PDR.
Clinical trials play a pivotal role in advancing the field of diabetic retinopathy management by evaluating the safety and efficacy of new treatments and interventions. Pharmaceutical companies and academic institutions are conducting numerous clinical trials to assess the effectiveness of investigational drugs, devices, and treatment strategies in patients with PDR. These trials not only contribute to the expansion of treatment options but also provide valuable data that informs clinical practice guidelines and improves patient care. As ongoing research continues to uncover new insights into the pathophysiology of PDR and identify innovative therapeutic approaches, the outlook for patients with proliferative diabetic retinopathy is expected to improve, driving further growth in the global market for PDR therapeutics and devices.
Competitive Landscape Analysis
Key players in Global Proliferative Diabetic Retinopathy Market include:
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Roche Holding AG
- Bayer AG
- Allergan plc
- Genentech, Inc. (a subsidiary of Roche)
- Alimera Sciences, Inc.
- Bausch Health Companies Inc.
- Santen Pharmaceutical Co., Ltd.
- Graybug Vision, Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Mode of Administration
- Market Snapshot, By Region
- Global Proliferative Diabetic Retinopathy Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Prevalence of Diabetes
- Advancements in Treatment Modalities
- Growing Awareness of Diabetic Retinopathy Screening
- Restraints
- Limited Access to Healthcare Services
- High Cost of Treatments and Devices
- Economic Factors and Reimbursement Policies
- Opportunities
- Development of Novel Drug Delivery Systems
- Expansion of Screening Programs
- Ongoing Research and Development Efforts
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Proliferative Diabetic Retinopathy Market, By Drug Class, 2021 - 2031 (USD Million)
- Anti-VEGF
- Corticosteroids
- Global Proliferative Diabetic Retinopathy Market, By Mode of Administration, 2021 - 2031 (USD Million)
- Injectables
- Oral
- Others
- Global Proliferative Diabetic Retinopathy Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Proliferative Diabetic Retinopathy Market, By Drug Class, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Roche Holding AG
- Bayer AG
- Allergan plc
- Genentech, Inc. (a subsidiary of Roche)
- Alimera Sciences, Inc.
- Bausch Health Companies Inc.
- Santen Pharmaceutical Co., Ltd.
- Graybug Vision, Inc.
- Company Profiles
- Analyst Views
- Future Outlook of the Market